LLYLilly (Eli)

Healthcare

$1,178.51+55% 1Y

$1,178.51

$711.1352 weeks$1.3K

Price

+55%1Y

End-of-day closes, not the intraday tick.

More going right than wrong

Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.

RyuScore 63 of 100: see how it is built

What they do

We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries.

In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR

P/E39.5

Market value$979.64B

1 year+55%

5 years+418%

Charts

As reported to the SEC, without any scoring.

Lilly (Eli) (LLY) reported revenue of $23.0B in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $7.09B (31% of revenue). For the full year FY2025, revenue was $65.2B (+45% year on year) and net income $20.6B. Its largest product in Q2 2026 was Cardiometabolic Health at $11.7B, 47% of the disclosed total, well ahead of Mounjaro at 19%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

May 20, 2026On May 20, 2026, Eli Lilly and Company (the “Company”) completed its offering of $750,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”), $500,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “2029 Floating Rate Notes” and, together with …Other event · Form 8-K
Nov 21, 2025On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.